This analyst putting the market at $10 Billion . Read what he said :
""""Vivus is competing with Orexigen and Arena, both of San Diego, to introduce a new diet drug in the U.S., a market that might be worth $10 billion annually for a safe therapy that help patients lose 10% of their weight in a year, said Needham & Co. analyst Mark Monane . Global obesity levels will swell 75 percent to 700 million people by 2015""
This is why JPM bought 1.4 mil shares at $10.50 . they know they make a bundle on this stock otherwise they would not have spent $10 million dollars
If HGSI's secondary closing happened on 8/3, the lowest low of the day I have during regular market hours was $14.17 on 8/7. I don't see it ever going to $12.70 after the secondary during regular market trading.
I read that fen fen was making 6 billion when it got puld off the market and this will be used for diabetes as well as obesity. So it's got to be more then the 1 billion we ben hearing about. sory about spelling.
$5+ bln sales for a high efficiant obesity drug like Qnexa is absolutely possible and this drug is safe. Trials showed, that in only 12 weeks average weight loss was around 10%. You need 52 weeks to achieve that weight loss with competitor drugs Lorcaserin and Contrave. So, Qnexa will be the choice not only for obese patients also for overweight people, who want to lose a few lbs very, very fast. Qnexa will be the fat wonder pill.